BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11

Benzinga Newsdesk www.benzinga.com Neutral 51.4%

Neg 0% Neu 51.4% Pos 0%

BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.